Published July 5, 2016 This content is archived.
The loss of brain tissue, called brain atrophy, is a normal part of aging, but multiple sclerosis (MS) accelerates the process. Such atrophy is a critical indicator of physical and cognitive decline in MS, yet because measuring brain atrophy is expensive and complicated, it’s done primarily in research settings.
That may be changing. Starting this month, UB researchers will be testing in the U.S., Europe, Australia and Latin America a new software tool they developed that could make assessing brain atrophy part of the clinical routine for MS patients. The research is funded by Novartis as part of its commitment to advance the care for people with MS with effective treatments and tools for assessment of disease activity.
According to the UB researchers, being able to routinely measure how much brain atrophy has occurred would help physicians better predict how a patient’s disease will progress. It also could provide physicians with more information about how well MS treatments are working in individual patients. These and other benefits were outlined in a recent review study the researchers published in Expert Review of Neurotherapeutics.
“Measuring brain atrophy on an annual basis will allow clinicians to identify which of their patients is at highest risk for physical and cognitive decline,” says Robert Zivadinov, professor of neurology and director of the Buffalo Neuroimaging Analysis Center in the Jacobs School of Medicine and Biomedical Sciences.
Over the past 10 years, he and his colleagues at UB, among the world’s most prolific groups studying brain atrophy and MS, developed the world’s largest database of magnetic resonance images of individuals with MS, consisting of 20,000 brain scans with data from about 4,000 MS patients. The new tool, Neurological Software Tool for Reliable Atrophy Measurement in MS, or NeuroSTREAM, simplifies the calculation of brain atrophy based on data from routine magnetic resonance images and compares it with other scans of MS patients in the database.
Without measuring brain atrophy, clinicians cannot obtain a complete picture of how a patient’s disease is progressing, Zivadinov says.
“MS patients experience, on average, about three to four times more annual brain volume loss than a healthy person,” he explains. “But a clinician can’t tell a patient, ‘You have lost this amount of brain volume since your last visit.’”
Instead, clinicians rely primarily on the presence of brain lesions to determine how MS is progressing. “Physicians and radiologists can easily count the number of new lesions on an MRI scan,” Zivadinov says, “but lesions are only part of the story related to development of disability in MS patients.”
And even though MS drugs can stop lesions from forming, in many cases brain atrophy and the cognitive and physical decline it causes will continue, the researchers say.
“While the MS field has to continue working on solving challenges related to brain atrophy measurement on individual patient level, its assessment has to be incorporated into treatment monitoring because in addition to assessment of lesions, it provides an important additional value in determining or explaining the effect of disease-modifying drugs,” Zivadinov and co-authors wrote in a June 23 editorial that was part of a series of commentaries in Multiple Sclerosis Journal addressing the pros and cons of using brain atrophy to guide therapy monitoring in MS.
Soon, the UB researchers will begin gathering data to create a database of brain volume changes in more than 1,000 patients from 30 MS centers in the U.S. and around the world. The objective is to determine if NeuroSTREAM can accurately quantify brain volume changes in MS patients.
The software runs on a user-friendly, cloud-based platform that provides compliance with privacy health regulations such as HIPAA. It is easily available from workstations, laptops, tablets, iPads and smartphones. The ultimate goal is to develop a user-friendly website to which clinicians can upload anonymous scans of patients and receive real-time feedback on what the scans reveal.
NeuroSTREAM measures brain atrophy by measuring a certain part of the brain, called the lateral ventricular volume (LVV), one of the brain structures that contains cerebrospinal fluid. When atrophy occurs, the LVV expands.
“The ventricles are a surrogate measure of brain atrophy,” says Michael G. Dwyer III, assistant professor in the departments of Neurology and Bioinformatics in the Jacobs School of Medicine and Biomedical Sciences. “They’re the canary in the coal mine.”
Dwyer, a computer scientist and director of technical imaging at the Buffalo Neuroimaging Analysis Center, is principal investigator on the NeuroSTREAM software development project. At the American Academy of Neurology meeting in April, he reported preliminary results showing that NeuroSTREAM provided a feasible, accurate, reliable and clinically relevant method of measuring brain atrophy in MS patients, using LVV.
“Usually, you need high-resolution research-quality brain scans to do this,” Dwyer explains, “but our software is designed to work with low-resolution scans, the type produced by the MRI machines normally found in clinical practice.”
To successfully measure brain atrophy in a way that’s meaningful for treatment, Zivadinov says what’s needed is a normative database through which individual patients can be compared to the population of MS patients. “NeuroSTREAM provides context because it compares a patient’s brain not just to the general population but to other MS patients,” Dwyer says.
The UB database was developed with patients seen at the Jacobs MS Center for Treatment and Research, a clinical partner of the Jacobs School of Medicine and Biomedical Sciences’ Department of Neurology, located at the Buffalo General Medical Center.